口腔の健康と歯の管理

概要

Clinical Efficacy of Recombinant Activated Factor VII for Haemophilia Patients Requiring Dental Treatment

Mihaela Maria Ghinea, Zizi Niculescu, Stoian F3, Gabriela Lilios

Introduction. Haemophilia is a group of sex-related recessive-transmission hereditary genetic disorders characterized biologically by quantitative deficit of either factor VIII or factor IX. Product NovoSeven (rFVIIa) is an important alternative treatment for any form of hemorrhage in haemophilia patients. Material and method. This study surveys 7 haemophilia patients admitted in the Department of Haematology at the Emergency Clinical County Hospital Constan?a for episodes of oral cavity hemorrhage (3 cases), or in preparation for dental interventions (dental extractions or other dental surgery interventions ? 4 cases). NovoSeven (rFVIIa) was administered in intravenous drip or bolus. Results and discussions. Treatment response was considered efficient in all 7 cases. In the 3 cases admitted for prolonged bleeding following dental extraction, administration at 3-hour intervals for 24 hours was necessary in 2 cases, and for 36 hours in 1 case. In the 4 cases in preparation for dental extractions and dental surgery, one dose before and after the intervention was sufficient. Prothrombine Time (PT) is useful in monitoring this treatment for haemophilia patients. Conclusion. NovoSeven (rFVIIa) treatment is efficient in controlling hemorrhagic manifestations occurring after dental interventions in haemophilia patients and in the prophylaxy of post-dental extraction bleeding.